Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Dyslipidaemia including decreased high density lipoprotein cholesterol concentration is one of several factors that have been implicated in increased cardiovascular risk. Since their introduction in the 1980s, 3-hydroxy-3-methyl- glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have emerged as the one of the best-selling class of medications to date, with numerous trials demonstrating powerful efficacy in preventing cardiovascular diseases. Although statins have been shown to modestly raise or not alter HDL-cholesterol, their effect on HDL subfractions and on HDL-associated enzymes including human paraoxonase-1 (PON1) has not yet been fully explored. This review summarizes the currently availabe data on the effect of statins on HDL subfractions and on PON1 activity with a particular emphasis on the clinical relevance of these effects. Moreover, methodological problems of HDL subfraction and PON1 activity determinations are also discussed.

Original languageEnglish
Pages (from-to)501-510
Number of pages10
JournalCardiovascular Drugs and Therapy
Volume23
Issue number6
DOIs
Publication statusPublished - Dec 1 2009

Keywords

  • High-density lipoprotein subfractions
  • Paraoxonase
  • Statin

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment'. Together they form a unique fingerprint.

  • Cite this